These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 18463974)
1. Ten years of HER2-directed therapy: still questions after all these years. Krop IE; Winer EP Breast Cancer Res Treat; 2009 Jan; 113(2):207-9. PubMed ID: 18463974 [No Abstract] [Full Text] [Related]
2. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer. Cameron DA; Stein S Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499 [TBL] [Abstract][Full Text] [Related]
3. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm]. Dalmases A; Rojo F; Rovira A; Albanell J Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407 [No Abstract] [Full Text] [Related]
4. [Lapatinib treatment-option in trastuzumab-resistant breast cancer]. Pikó B Magy Onkol; 2009 Dec; 53(4):369-75. PubMed ID: 20071309 [TBL] [Abstract][Full Text] [Related]
5. Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer. Morrow PK; Zambrana F; Esteva FJ Breast Cancer Res; 2009; 11(4):207. PubMed ID: 19664181 [TBL] [Abstract][Full Text] [Related]
6. Targeting alternative pathways in HER2-positive breast cancer. Rastogi P Oncology (Williston Park); 2010 Apr; 24(5):415-6. PubMed ID: 20480739 [No Abstract] [Full Text] [Related]
7. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114 [TBL] [Abstract][Full Text] [Related]
8. Update on HER-kinase-directed therapy in prostate cancer. Gross ME; Jo S; Agus DB Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160 [TBL] [Abstract][Full Text] [Related]
9. Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer. Cameron D Clin Adv Hematol Oncol; 2007 Jun; 5(6):456-8. PubMed ID: 17679920 [No Abstract] [Full Text] [Related]
10. Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer. Guarneri V Expert Rev Anticancer Ther; 2009 Nov; 9(11):1549-57. PubMed ID: 19895239 [TBL] [Abstract][Full Text] [Related]
11. Anti-epidermal growth factor receptor strategies for advanced breast cancer. Campos SM Cancer Invest; 2008 Oct; 26(8):757-68. PubMed ID: 18853311 [No Abstract] [Full Text] [Related]
12. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126 [TBL] [Abstract][Full Text] [Related]
13. Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine. Liu Z; Fusi A; Schmittel A; Tinhofer I; Schneider A; Keilholz U Cancer Biol Ther; 2010 Nov; 10(9):860-4. PubMed ID: 20855957 [TBL] [Abstract][Full Text] [Related]
14. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Cameron D; Casey M; Press M; Lindquist D; Pienkowski T; Romieu CG; Chan S; Jagiello-Gruszfeld A; Kaufman B; Crown J; Chan A; Campone M; Viens P; Davidson N; Gorbounova V; Raats JI; Skarlos D; Newstat B; Roychowdhury D; Paoletti P; Oliva C; Rubin S; Stein S; Geyer CE Breast Cancer Res Treat; 2008 Dec; 112(3):533-43. PubMed ID: 18188694 [TBL] [Abstract][Full Text] [Related]
15. [Docetaxel (Taxotere) in combination with anthracycline, capecitabin (Xeloda) and new drugs]. Galligioni E Tumori; 2001; 87(1 Suppl 2):S1-9. PubMed ID: 11357871 [No Abstract] [Full Text] [Related]
16. ErbB/HER receptor family in breast cancer--the more we search the more we learn. Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG Ann Oncol; 2008 May; 19(5):1020-1. PubMed ID: 18356136 [No Abstract] [Full Text] [Related]
17. [Metastatic breast cancer--new methods of treatment]. Rack B; Heinemann V; Schindlbeck C; Walther J; Salat C; Sommer H MMW Fortschr Med; 2008 Jan; 150(1-2):34-6. PubMed ID: 18300641 [No Abstract] [Full Text] [Related]
18. Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available. Bianchi GV; Duca M; Sica L; Mariani G Tumori; 2013; 99(6):269e-72e. PubMed ID: 24503801 [TBL] [Abstract][Full Text] [Related]